Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Quantitating the Impact of Plerixafor Alone or in Combination With Bortezomib on Plasma Cell Mobilization and the Subsequent Impact on HLA Antibody Levels

Next Previous
Trial Profile

Quantitating the Impact of Plerixafor Alone or in Combination With Bortezomib on Plasma Cell Mobilization and the Subsequent Impact on HLA Antibody Levels

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Jun 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Plerixafor (Primary) ; Bortezomib
  • Indications Stem cell mobilisation
  • Focus Pharmacodynamics; Proof of concept

Most Recent Events

  • 29 Jun 2020 Planned End Date changed from 1 Dec 2019 to 1 Oct 2020.
  • 29 Jun 2020 Planned primary completion date changed from 1 Sep 2019 to 1 Sep 2020.
  • 19 Apr 2019 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top